Drug intelligence / Profile preview

UK-432097

Development stage: Discontinued
Lead developer: Pfizer
Modality: Small Molecules
Administration: Inhalation

Overview

UK-432097 is a potent and selective small molecule agonist of the adenosine A2A receptor developed by Pfizer for the treatment of chronic obstructive pulmonary disease (COPD). It was formulated as an inhaled dry powder and administered using an atomizer device. Despite its high selectivity and strong stabilizing effect on the A2A receptor—making it valuable for structural studies—the drug was discontinued after Phase 2 clinical trials due to poor efficacy in humans. Its pharmacological profile includes a slow off-rate from the receptor and extensive ligand-receptor interactions that contribute to its high binding affinity.

Other names: 380221-63-6UNII-8L3OAJ1R5AUNII8L3OAJ1R5AUNII 8L3OAJ1R5A8L3OAJ1R5A

Targets

ADORA2A (Adenosine A₂A Receptor)

Beyond the preview

Go deeper on UK-432097.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UK-432097.

Explore the full profile